BiotechTube

Octreotide + Placebo

Pre-clinicalTerminated
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

Dec 1, 2006 → Sep 1, 2010

NCT ID
NCT00399893

About Octreotide + Placebo

Octreotide + Placebo is a pre-clinical stage product being developed by Novartis for Prader-Willi Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00399893. Target conditions include Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT00426153Phase 2/3Completed
NCT00399893Pre-clinicalTerminated

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Norditropin SimpleXxNovo NordiskPre-clinical
22
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
76
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 2
49
SetmelanotideRhythm PharmaceuticalsPhase 2
49
RGH-706 + PlaceboRichter GedeonPhase 2
49
CarbetocinAcadia PharmaceuticalsPhase 3
72
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
DCCRSoleno TherapeuticsPhase 3
72
DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
PitolisantHarmony BiosciencesPhase 3
72
Pitolisant tabletHarmony BiosciencesPhase 3
72
Pitolisant oral tablets + Placebo oral tabletHarmony BiosciencesPhase 2
47
DCCRSoleno TherapeuticsPhase 3
72
VYKAT XRSoleno TherapeuticsPre-clinical
18
DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
NNZ-2591Neuren PharmaceuticalsPhase 2
47
BMB-101 + PlaceboBright Minds BiosciencesPhase 2
47
ARD-101Aardvark TherapeuticsPhase 2
44

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85